c/survodutide · created 14 Feb 2024
GLP-1/glucagon dual agonist. MASH data and the hepatic angle.
Posting this because I searched for it and got nothing useful. Setup: 15mg, week 49, sulphur burps present but not ruining anything. I changed exactly one variable —…
The phase 2 MASH results ( NEJM , 2024) are, to me, the most underdiscussed thing in this whole space. Biopsy-confirmed endpoints. Not an ALT screenshot, not imaging,…
Trying to settle this properly because the thread from last year went in circles. The claim: MASH matters. The counter-claim: it is measurement error. Both sides have…
Confession thread, sort of. I went from 2.4mg to 0.5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 5 weeks…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsSurvodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference